CA3225467A1 - Phenol derivatives for use in the modulation of brm - Google Patents
Phenol derivatives for use in the modulation of brm Download PDFInfo
- Publication number
- CA3225467A1 CA3225467A1 CA3225467A CA3225467A CA3225467A1 CA 3225467 A1 CA3225467 A1 CA 3225467A1 CA 3225467 A CA3225467 A CA 3225467A CA 3225467 A CA3225467 A CA 3225467A CA 3225467 A1 CA3225467 A1 CA 3225467A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- compound
- pharmaceutically acceptable
- tautomer
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231220P | 2021-08-09 | 2021-08-09 | |
| US202163231219P | 2021-08-09 | 2021-08-09 | |
| US63/231,219 | 2021-08-09 | ||
| US63/231,220 | 2021-08-09 | ||
| PCT/US2022/039696 WO2023018648A1 (en) | 2021-08-09 | 2022-08-08 | Phenol derivatives for use in the modulation of brm |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3225467A1 true CA3225467A1 (en) | 2023-02-16 |
Family
ID=83149068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3225467A Pending CA3225467A1 (en) | 2021-08-09 | 2022-08-08 | Phenol derivatives for use in the modulation of brm |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11993599B2 (enExample) |
| EP (1) | EP4384517A1 (enExample) |
| JP (1) | JP2024533990A (enExample) |
| KR (1) | KR20240046498A (enExample) |
| AU (1) | AU2022328137A1 (enExample) |
| CA (1) | CA3225467A1 (enExample) |
| TW (1) | TW202321250A (enExample) |
| WO (1) | WO2023018648A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3225467A1 (en) | 2021-08-09 | 2023-02-16 | Genentech, Inc. | Phenol derivatives for use in the modulation of brm |
| EP4540242A1 (en) * | 2022-06-16 | 2025-04-23 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a |
| WO2024214019A1 (en) | 2023-04-12 | 2024-10-17 | Aurigene Oncology Limited | Tetracyclic compounds as smarca2 and/or smarca4 degraders |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2019207538A1 (en) | 2018-04-26 | 2019-10-31 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as smarca2/4 degraders |
| EP3787747A4 (en) | 2018-04-30 | 2022-01-12 | Dana-Farber Cancer Institute, Inc. | POLYBROMO-1 (PBRM1) SMALL MOLECULE DEGRADATION PRODUCTS |
| EP3817822A4 (en) * | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020078933A1 (en) | 2018-10-16 | 2020-04-23 | Boehringer Ingelheim International Gmbh | Proteolysis targeting chimera (protacs) as degraders of smarca2 and/or smarca4 |
| FR3090393B1 (fr) | 2018-12-20 | 2021-04-23 | Ifp Energies Now | Procédé de traitement d’une charge alcool pour la production d’oléfines |
| WO2020172655A1 (en) | 2019-02-23 | 2020-08-27 | New York University | Photoswitchable protacs and synthesis and uses thereof |
| WO2020251971A1 (en) * | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| US20220324880A1 (en) * | 2019-06-10 | 2022-10-13 | Kymara Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| WO2020251969A1 (en) * | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| BR112022004573A2 (pt) | 2019-09-12 | 2022-06-07 | Aurigene Discovery Tech Ltd | Método para identificar respondedores para degradadores de smarca2/4 |
| WO2021067606A1 (en) * | 2019-10-01 | 2021-04-08 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| EP4054724A4 (en) | 2019-10-28 | 2023-12-27 | C4 Therapeutics, Inc. | BIFUNCTIONAL CONNECTIONS |
| CN114728936A (zh) * | 2019-10-29 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的双功能化合物 |
| JP7706456B2 (ja) | 2020-01-10 | 2025-07-11 | アムジエン・インコーポレーテツド | Ｓｍａｒｃａ２－ｖｈｌ分解剤 |
| EP4132529A4 (en) | 2020-04-06 | 2024-05-01 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| JP2023529908A (ja) * | 2020-06-09 | 2023-07-12 | プレリュード・セラピューティクス・インコーポレイテッド | Ｂｒｍ標的化化合物及び関連する使用方法 |
| TW202216215A (zh) * | 2020-07-21 | 2022-05-01 | 美商建南德克公司 | Ｂｒｍ降解之抗體結合化學誘導物及其方法 |
| WO2022109396A1 (en) | 2020-11-20 | 2022-05-27 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| WO2022183056A1 (en) | 2021-02-26 | 2022-09-01 | Salk Institute For Biological Studies | Modulating regulatory t cell function in autoimmune disease and cancer |
| CA3225467A1 (en) | 2021-08-09 | 2023-02-16 | Genentech, Inc. | Phenol derivatives for use in the modulation of brm |
-
2022
- 2022-08-08 CA CA3225467A patent/CA3225467A1/en active Pending
- 2022-08-08 WO PCT/US2022/039696 patent/WO2023018648A1/en not_active Ceased
- 2022-08-08 KR KR1020247004828A patent/KR20240046498A/ko active Pending
- 2022-08-08 US US17/883,004 patent/US11993599B2/en active Active
- 2022-08-08 AU AU2022328137A patent/AU2022328137A1/en active Pending
- 2022-08-08 JP JP2024507995A patent/JP2024533990A/ja active Pending
- 2022-08-08 EP EP22761812.1A patent/EP4384517A1/en active Pending
- 2022-08-09 TW TW111129895A patent/TW202321250A/zh unknown
-
2024
- 2024-03-13 US US18/604,314 patent/US12428419B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4384517A1 (en) | 2024-06-19 |
| KR20240046498A (ko) | 2024-04-09 |
| US12428419B2 (en) | 2025-09-30 |
| WO2023018648A1 (en) | 2023-02-16 |
| AU2022328137A1 (en) | 2024-02-01 |
| US20240383897A1 (en) | 2024-11-21 |
| US20230112485A1 (en) | 2023-04-13 |
| TW202321250A (zh) | 2023-06-01 |
| US11993599B2 (en) | 2024-05-28 |
| JP2024533990A (ja) | 2024-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021248415B2 (en) | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of diseases associated with PI3K modulation | |
| CN112778276B (zh) | 作为shp2抑制剂的化合物及其应用 | |
| JP7300460B2 (ja) | 置換１，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン | |
| ES2548532T3 (es) | Compuestos de pirrolopirimidina como inhibidores de CDK4/6 | |
| US20240025907A1 (en) | QUINAZOLINE PAN-KRas INHIBITORS | |
| EP3468960B1 (en) | Chemical compounds as atf4 pathway inhibitors | |
| US10450296B2 (en) | Heterocyclic compounds useful as Pim kinase inhibitors | |
| US20250368649A1 (en) | Tetrahydropyridopyrimidine pan-kras inhibitors | |
| WO2024238633A2 (en) | Kras g12s and g12c inhibitors | |
| WO2023066350A1 (zh) | Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用 | |
| US12162888B2 (en) | Carboxamides as ubiquitin-specific protease inhibitors | |
| US12428419B2 (en) | Therapeutic compounds | |
| CA2889526C (en) | 2-aminopyridine compounds | |
| CA2931758A1 (en) | Fused tricyclic imidazole derivatives as modulators of tnf activity | |
| US20240246977A1 (en) | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use | |
| US11524966B1 (en) | Carboxamides as ubiquitin-specific protease inhibitors | |
| US20240366770A1 (en) | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use | |
| US20240034731A1 (en) | Aza-quinazoline compounds and methods of use | |
| JP2025538190A (ja) | Ｅｇｆｒキナーゼの分解のための化合物 | |
| EP4493545A2 (en) | Fused pyrazole amide analogs as glucosylceramide synthase inhibitors | |
| CN117794933A (zh) | 用于调节brm的酚衍生物 | |
| CA3173569C (en) | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease | |
| HK40111551A (zh) | 用於调节brm的酚衍生物 | |
| US20250235456A1 (en) | Methods of use for aza-quinazoline compounds | |
| WO2023172475A2 (en) | Non-aromatic cyclic-pyrimidine analogs as glucosylceramide synthase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250723 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250723 |